...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cellular immunology >FoxP3+, and not CD25+, T cells increase post-transplant in islet allotransplant recipients following anti-CD25+ rATG immunotherapy
【24h】

FoxP3+, and not CD25+, T cells increase post-transplant in islet allotransplant recipients following anti-CD25+ rATG immunotherapy

机译：抗CD25 + rATG免疫疗法后，胰岛同种异体移植受体的FoxP3 +而非CD25 + T细胞增加

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Anti-CD25 antibodies are used as an induction therapy in islet allotransplantation for type 1 diabetes. Although previous reports suggested that anti-CD25 treatment may lead to depletion of CD4+CD25+ regulatory T cells (Tregs) and questioned its use in tolerance-promoting protocols for transplantation, the effect of anti-CD25 antibodies on the frequency and function of Tregs remains unclear. We examined the effect of anti-CD25 antibody, daclizumab, in vivo on Tregs in islet allograft recipients enrolled in a single-center study and monitored post-transplant. Our data shows that the reduction in CD25+ Treg cells observed post-transplant is due to masking of CD25 receptor by daclizumab and not due to depletion. In addition, using Treg marker, FoxP3, we show that anti-CD25+ ATG treatment leads to an increase in FoxP3+ Tregs post-transplant. These data suggest that anti-CD25-based therapy has beneficial effects on Tregs and combined with ATG may be a promising therapy for autoimmunity and transplantation.
机译：抗CD25抗体在胰岛同种异体移植中用于1型糖尿病的诱导治疗。尽管先前的报道表明抗CD25治疗可能导致CD4 + CD25 +调节性T细胞（Tregs）耗竭，并质疑其在促进耐受性的移植方案中的用途，但抗CD25抗体对Tregs频率和功能的影响仍然存在不清楚。我们在单中心研究中检测了胰岛同种异体移植受者体内抗CD25抗体达珠单抗在体内对Treg的影响，并监测了移植后的情况。我们的数据表明，移植后观察到的CD25 + Treg细胞减少是由于达克里珠单抗掩盖了CD25受体，而不是由于耗竭。此外，使用Treg标记FoxP3，我们显示抗CD25 + ATG处理导致移植后FoxP3 + Treg的增加。这些数据表明，基于抗CD25的疗法对Treg具有有益作用，并且与ATG联合使用可能是一种有希望的自身免疫和移植疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号